DALLAS, Nov. 25, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring ARCA biopharma Inc. (Nasdaq:ABIO). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on ARCA biopharma Inc. (Nasdaq:ABIO) should be of particular interest to other drug manufacturers: Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://www.investorsoup.com/lp/ABIO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
ARCA biopharma Inc. (ABIO), formerly Nuvelo Inc., is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator, is under review by the U.S. Food and Drug Administration (FDA) for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily.
Message Board Search for ABIO: http://www.boardcentral.com/boards/ABIO
In the report, the analyst notes:
"ABIO's R&D expenses were $9.2 million for the nine months ended September 30, 2009, as compared to $8.4 million for the corresponding period of 2008, an increase of approximately $850,000. For the nine months ended September 30, 2009, clinical study costs increased approximately $2.2 million for clinical development projects initiated by Nuvelo on the NU 172 and NU 206 compounds obtained in the merger.
"ABIO recently announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Gencaro(TM), the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. The Company intends to submit a study protocol for review under the FDA's Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of Gencaro in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro."
To read the entire report visit: http://www.investorsoup.com/lp/ABIO
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.